Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 3Adenocarcinoma 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Valacyclovir × Genitourinary × Clear all
NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02768363 2025-07-30

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Candel Therapeutics, Inc.

Phase 2 Active not recruiting
187 enrolled
Genitourinary

Prostatic Neoplasms

NCT03541928 2021-04-06

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

The Methodist Hospital Research Institute

Phase 2 Unknown
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡